Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders

• Status: Active, not recruiting
• Trial end date: 2021-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

During ovarian stimulation, all the follicles grow under the action of FSH, only the selected follicles and with the faster growth are taken. However during this stimulation, other smaller follicles are also recruited and sensitized, which may increase the selection of follicles available on the follicular wave following. In patients with weak reserve this potentiation has a great interest, and the sequence of 2 stimulations on the same cycle could make it possible to obtain a larger number of oocytes and embryos, thus giving a better chance of delivery than on 2 distinct cycles of stimulation. However, this is preliminary data that needs to be confirmed with a randomized controlled trial. In this population of poor prognosis, the use of FSH-associated LH activity may optimize the ovarian response to stimulation, particularly the combination containing placental HCG (Fertistartkit®) that obtaining a slightly higher number of oocytes than highly purified HMG (Menopur®).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Intercommunal Creteil
• Collaborators: IBSA Institut Biochimique SA; Laboratoires Genévrier

Criteria

Inclusion Criteria:

• Women from 20 to 41 years old

• CFA <5 and / or AMH <1, 2 ng / ml

• 19 ≤ BMI ≤ 32

• Supports IVF or ICSI

• If antecedent IVF / ICSI, number of oocytes collected <4

• Attack rank (puncture with transfer) <3

• Affiliation to the general social security scheme and benefiting from 100% infertility

Exclusion Criteria:

• Confirmed ovarian insufficiency (amenorrhea)

• FSH> 20 IU / l or CFA <1

• Puncture rank> 3

• Azoospermia or cryptozoospermia

• Against indication to ovarian stimulation

• Presence of a cyst of indeterminate etiology, ovarian, uterine or mammary carcinoma, hypothalamic or pituitary tumors

• Hypersensitivity to any of the medicines in the protocol

• Moderate or severe pathology of renal or hepatic function

• Evolutionary thromboembolic accidents